Crescent Biopharma Announces Grants of Inducement Awards

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) announced inducement equity awards approved March 26, 2026. The independent Compensation Committee granted options to purchase a total of 35,325 ordinary shares to three non-executive employees under the 2025 Inducement Plan.

The options have a 10-year term, an exercise price of $13.50 (Nasdaq close on March 26, 2026), and vest 25% after one year then monthly thereafter (1/48th per month), subject to continuous service and plan terms.

Key Figures

Current share price: $13.50 Inducement option shares: 35,325 shares Number of employees: 3 employees +3 more

6 metrics

Current share price $13.50 Nasdaq close on March 26, 2026 used as option exercise price

Inducement option shares 35,325 shares Aggregate options granted to three non-executive employees

Number of employees 3 employees Recipients of equity inducement option awards

Option term 10-year term Duration of inducement stock options

Initial vesting portion 1/4 of shares Vests on first anniversary of each employee’s start date

Ongoing vesting rate 1/48 of shares Monthly vesting after first anniversary, subject to service

Market Reality Check

Price: $15.18 Vol: Volume 448,744 is 2.4x th...

high vol

$15.18 Last Close

Volume Volume 448,744 is 2.4x the 20-day average of 186,930, signaling elevated trading interest pre-announcement. high

Technical Shares at $13.50 are trading above the 200-day MA of $12.35 and sit at the 52-week low of $13.50, 36.92% below the $21.40 52-week high.

Peers on Argus

CBIO gained 14.6% with elevated volume, while momentum data flagged only one pee...

1 Down

CBIO gained 14.6% with elevated volume, while momentum data flagged only one peer (TVGN) moving down and sector peers showed mixed moves (e.g., CRBU up 4.62%, IPHA down 4.09%), pointing to a stock-specific move.

Historical Context

5 past events · Latest: Mar 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Inducement option grants	Neutral	-0.4%	Grant of 45,675-share inducement options with 10-year term at $11.33.
Feb 26	Earnings and updates	Neutral	-1.2%	Q4 and 2025 results plus Kelun-Biotech partnership and $185M placement.
Feb 23	Investor conferences	Neutral	-1.6%	March 2026 investor conference presentations with webcast access for 90 days.
Feb 19	Inducement option grants	Neutral	+20.8%	24,600-share inducement options with 10-year term at $9.33.
Feb 18	Clinical trial start	Positive	+4.2%	First patient dosed in ASCEND Phase 1/2 trial of CR-001 in solid tumors.

Pattern Detected

Recent CBIO news has usually led to modest single‑digit moves, with one prior inducement‑grant headline coinciding with a larger 20.78% gain, suggesting occasional outsized reactions to routine updates.

Recent Company History

Over the past months, Crescent Biopharma has combined routine corporate updates with material pipeline and financing milestones. Inducement award grants on Feb 17 and Mar 5, 2026 involved relatively small option packages and produced mixed price reactions, while a key ASCEND Phase 1/2 trial milestone on Feb 18, 2026 brought a 4.18% gain. Earnings and conference announcements in late February were followed by modest declines. Today’s inducement awards echo those earlier HR-focused grants.

Market Pulse Summary

This announcement details option grants for 35,325 shares at an exercise price of $13.50 to three no...

Analysis

This announcement details option grants for 35,325 shares at an exercise price of $13.50 to three non‑executive employees under an inducement plan, with standard four‑year vesting. Similar awards were disclosed in February and March 2026, while more material developments included ASCEND trial progress and 2025 financial results. Investors may watch how ongoing hiring, trial execution, and follow‑on disclosures about CR‑001 and related programs evolve alongside these routine equity incentives.

Key Terms

nasdaq listing rule 5635(c)(4), equity inducement awards, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity inducement awards financial

"as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

exercise price financial

"an exercise price equal to $13.50, the closing price per share of Crescent’s"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 35,325 shares of the Company’s ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on March 26, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $13.50, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on March 26, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contact

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

FAQ

What equity awards did Crescent Biopharma (CBIO) grant on March 26, 2026?

The company granted options to purchase an aggregate of 35,325 ordinary shares to three non-executive employees. According to Crescent Biopharma, the grants were approved by the independent Compensation Committee under the 2025 Inducement Plan as inducement awards.

What is the exercise price and term of the CBIO inducement options granted March 26, 2026?

The inducement options carry an exercise price of $13.50 and a 10-year term. According to Crescent Biopharma, $13.50 equals the Nasdaq closing price on March 26, 2026 and options expire ten years after grant.

How do the CBIO inducement options vest for employees hired under the 2025 Inducement Plan?

Options vest 25% after the first anniversary of employment, then 1/48th monthly thereafter. According to Crescent Biopharma, vesting is subject to continuous service and the specific option agreement terms.

Why were these CBIO option grants described as inducement awards under Nasdaq rules?

They were approved as inducement awards because they were material to each employee's acceptance of employment. According to Crescent Biopharma, the grants comply with Nasdaq Listing Rule 5635(c)(4) for employment inducement grants.

Will the CBIO inducement option grants cause immediate dilution for current shareholders?

The grants create potential future dilution if exercised, but immediate dilution depends on exercise timing and share count. According to Crescent Biopharma, the options total 35,325 shares and become dilutive only upon exercise at $13.50 per share.

Where can investors find the terms governing the CBIO inducement options granted March 26, 2026?

The options are subject to the Inducement Plan and individual option agreements specifying terms and conditions. According to Crescent Biopharma, the grants follow the 2025 Employment Inducement Incentive Award Plan, as amended.